Organization | Yorkshire Regional Clinical Trials Research Unit

Yorkshire Regional Clinical Trials Research Unit Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

1993

NCT00002582

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

1993

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (9)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

fluorouracil (efudex) (1 trial)

goserelin (zoladex) (1 trial)

leuprolide (lupron) (1 trial)

naltrexone (revia) (1 trial)

tamoxifen (nolvadex) (1 trial)

temsirolimus (torisel) (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial APIs: 9